Propanc Biopharma Inc

PPCB Healthcare Biotechnology

EPS
−99.6%
Free cash flow
−1,637.4%
Total debt
−21.4%

Quarter to June 2026, against a year earlier

1.79 0.15 +9.15%
Market cap
$1.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
2.55 2.37 2.13 2.45

+8 more quarters

Net Debt/EBITDA
0.11 0.00 0.01 0.02
Debt/Equity
0.05 0.05 0.05 0.04
Free Cash Flow per Share
(14.25) (12.74) (18.75) (39.38)
Book value per Share
83.65 109.56 195.74 291.30
Free Cash Flow
(1.60) (1.14) (1.00) (1.94)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026